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Abstract
Mutations in the δ-sarcoglycan gene cause limb-girdle muscular dystrophy 2F (LGMD2F), an autosomal recessive
disease that causes progressive weakness and wasting of the proximal limb muscles and often has cardiac
involvement. Here we review the clinical implications of LGMD2F and discuss the current understanding of the
putative mechanisms underlying its pathogenesis. Preclinical research has benefited enormously from various
animal models of δ-sarcoglycan deficiency, which have helped researchers to explore therapeutic approaches for
both muscular dystrophy and cardiomyopathy.
δ-Sarcoglycanopathy
Historical and clinical aspects
In 1954, Walton and Nattrass described a group of
patients who shared a similar pattern of proximal mus-
cle weakness and whose symptoms could not be
assigned to any of the known muscular dystrophies
(MDs) of that time [1]. This highly heterogeneous group
of patients was broadly characterised as having the
limb-girdle muscular dystrophies (LGMDs). It was not
until the discovery of dystrophin as the relevant protein
missing in Duchenne muscular dystrophy (DMD) [2,3]
and the isolation of the dystrophin glycoprotein complex
(DGC) [4] that this group was further stratified accord-
ing to the molecular defect. It is now known that a sub-
group of patients who present with an LGMD
phenotype harbour mutations in genes encoding four of
a family of six transmembrane proteins called the sarco-
glycans (SGs).
LGMD2F was the fourth of the sarcoglycanopathies
(LGMD2C to LGMD2F) to be characterised when the
causative mutation in the δ-SG gene was identified in a
group of Brazilian LGMD patients with a DMD-like pre-
sentation whose disease was linked to a region on chro-
mosome 5 (q33-34) [5-7]. Since then, a large number of
mutations causing both LGMD2F and δ-SG-associated
cardiomyopathy have been described (Leiden Muscular
Dystrophy database: http://www.dmd.nl/).
The age of onset in LGMD2F can vary from early
childhood to adulthood. Most patients present with pro-
gressive weakness and wasting of the proximal muscles
and elevated serum creatine kinase in the first decade of
life [8]. General survival depends on cardiac and respira-
tory involvement and patients can die, sometimes even
at early stages of the disease, because of severe dilated
cardiomyopathy or chest infections and respiratory fail-
ure [9,10]. The diagnosis is based initially on examina-
tion of a muscle biopsy (which exhibits dystrophic
features with reduced SG expression) and is confirmed
by genetics [11]. Sarcoglycanopathy has, as a whole, a
relatively low prevalence in nonconsanguineous popula-
tions (2.27/100,000 is a recent estimate) [12,13], and
whilst δ-sarcoglycanopathy seems to be the rarest of this
group of MDs [14], the understanding of its pathogen-
esis has implications for the development of therapeutic
approaches for both patients with MD and patients with
cardiomyopathy.
While patients with LGMD2F most commonly present
with skeletal muscle weakness and only develop cardio-
myopathy at later stages of their disease, δ-SG mutations
have also been found in patients with primary hereditary
dilated cardiomyopathy with no significant skeletal mus-
cle symptoms [15-18]. It has been suggested that at least
one of these mutations could cause mild pathology in
heterozygous carriers [18] or could even show a domi-
nant mode of inheritance [15], but further evidence is
necessary to clearly show that both recessive and domi-
nant mutations are responsible for δ-SG-deficient cardi-
omyopathy [19].
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The δ-SG gene contains nine exons spanning a 433-kb
region of genomic DNA. It encodes a 35-kDa, single-
pass, type II transmembrane glycoprotein. To understand
its role in the pathology of MD and cardiomyopathy, it is
important to consider it as one of a family of six SG pro-
teins, four of which, a-, b-, g-a n dδ-SG, are associated
with forms of autosomal recessive LGMD and cardio-
myopathy, and one of which, ε-SG, is associated with a
form of myoclonus dystonia, whereas no disease has been
associated with ζ-SG to date. g-a n dδ-SG share a similar
structure with a conserved sequence in the C-terminal
domain, which is essential for their localisation to the
plasma membrane, and an N-terminus that is important
for SG-SG interaction [20]. It is generally accepted that,
in skeletal muscle, at least a-, b-, and g-SG form a tetra-
meric complex with δ- S G .T h e r ei sa l s oe v i d e n c et h a tε-
SG can replace a-SG in striated muscle to form a second
SG complex [21].
Coimmunoprecipitation studies have shown a strong
interaction between δ-a n db-SG [22], which is thought
to form a central core that is necessary for the delivery
and retention of other SGs to the cell membrane
[23,24]. This hypothesis is supported by the fact that
patients with mutations in either δ-o rb-SG appear to
have a complete loss or a strong reduction of the whole
SG complex on examination of muscle biopsy samples
[14,25,26]. It is thought that in smooth muscle, ε-SG
functionally replaces a-SG to form a unique complex
analogous to that in skeletal muscle [27,28]. The more
recent discovery of ζ-SG in skeletal and smooth muscle
[29] has led to the prediction of other models of SG
complex conformation [30-32].
The various forms of SG complexes all seem to form
an integral part of the dystrophin-glycoprotein complex
(DGC) [33], the function of which has best been charac-
terised in skeletal muscle, where it forms a mechano-
signalling link between the F-actin cytoskeleton and the
extracellular matrix. The DGC confers structural stabi-
lity to the sarcolemma, and dissociation of the complex
by loss of one of its components renders the muscle
more susceptible to contraction-induced damage. Disso-
ciation of the DGC complex is also thought to have
widespread implications for a number of signalling pro-
cesses, as it is closely associated with a diverse range of
molecules, such as neuronal nitric oxide synthase
(nNOS) [34-36] and members of the integrin family of
signalling proteins [37-39].
An alternative splice variant of δ-SG, SG3, has been
localised to the membrane of the sarcoplasmic reticulum
(SR), where it forms a complex homologous to that at
t h es a r c o l e m m a[ 4 0 ] .I ti sh y p o t h e s i s e dt h a tt h i sS R
complex plays a role in regulating calcium movement
across the SR membrane, which is important for the
maintenance of calcium homeostasis.
Although the SGs are expressed primarily in muscle,
there is evidence that they are also expressed in other
tissues, such as myelin [41], adipocytes [42], kidney and
lung epithelial cells [28] and the retina [43]. The func-
tional relevance of SG expression in these tissues is cur-
rently unclear, however, as patients with LGMD2F do
not appear to show neuropathic, central nervous system
or cognitive impairments, nor do they have any overt
aberrations in glucose metabolism or kidney and lung
function.
Animal models of δ-SG deficiency
T h e r ea r ean u m b e ro fa n i m a lm o d e l so fδ-sarcoglyca-
nopathy that have aided in the understanding of its
pathogenesis (Table 1). The cardiomyopathic hamster is
the oldest and most well-characterised of these.
The cardiomyopathic hamster: a model of
sarcoglycanopathy in cognito
The BIO 14.6 hamster strain was established in 1962
[44] and was studied for over three decades as a model
of cardiomyopathy, but it was only after the discovery of
the causative mutation in LGMD2F patients that two
independent laboratories demonstrated a large deletion
in the 5’ end of the δ-SG gene in these animals [45,46].
The hamster was therefore heralded as the first animal
model of sarcoglycanopathy.
L i k et h em a j o r i t yo fL G M D 2 Fp a t i e n t s ,t h eh a m s t e r
lacks sarcolemmal δ-SG expression and has a concomi-
tant reduction in the other components of the SG com-
plex [47]. Cardiac damage could be seen in the heart
from 5 weeks of age, indicating the early onset of
pathology in cardiac muscle compared to skeletal mus-
cle [47]. Assessment of cardiac haemodynamics in the
hamster over its lifetime (240 days) indicates a cardio-
myopathic phenotype with decreased stroke volume and
cardiac output (CO) as well as increased ventricular
mass [48].
At least three additional strains of hamsters, the TO-2,
CHF147 (formally VMX7.1) and J2N-k strains, have
since arisen from the original BIO 14.6 strain. The TO-
2 strain is particularly interesting, as these hamsters
exhibit a more severe cardiomyopathy and a shorter life-
span than their BIO 14.6 counterparts. In addition,
while both strains share the same 30-kb deletion in the
δ-SG gene, the BIO 14.6 strain develops a hypertrophic
cardiomyopathy, whilst the TO-2 hamsters tend to
develop a severe dilated cardiomyopathy with a predo-
minantly necrotic mode of pathology [49,50]. This pre-
sents the intriguing possibility of the presence of a
genetic modifier within the TO-2 hamster. Indeed, a
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a
Species Genesis Effect on protein/DGC
components
Phenotype
Hamster
BIO 14.6 Naturally occurring, autosomal recessive
mutation (30-kb deletion in exons 1 and 2) [44]
Loss of δ- and b-SG
Reduction of a- and g-SG [47,54]
Reduction in a-dystroglycan [47]
Normal dystrophin
Compensatory hypertrophic CM leading to
dilated CM
Sarcolemmal damage (increased EBD uptake)
TO-2 Cross-breeding (30-kb deletion in exons 1 and 2) Complete loss of SG complex
Translocation of dystrophin to
cytoplasm [150]
Severe dilated CM
LV dysfunction from 8 weeks [151]
Gait disturbances [152]
J2N-k Cross-breeding (BIO 14.6 × golden hamster,
then consecutive sib mating) [153]
Uncharacterized? Cardiac contractile dysfunction
Dilated CM from 20 weeks [90]
Elevated CK level
UMX7.1 or
CHF147
Cross-breeding (BIO 14.6 × normal controls) [154] Uncharacterized? Dilated CM
Progressive LV dysfunction [155]
Reduced life expectancy (190 days)
Early skeletal muscle pathology (10 to 15 days)
Focal necrosis
Unselective muscle involvement
Mouse
Sgcd
-/-
(C57BL6
background)
Transgenic (vector-mediated, knockdown-
targeted replacement of exon 2, which
encodes the entire TM domain and part of the
intracellular domain) [57]
Loss of whole SG complex and
sarcospan
Limb-girdle pattern of muscle involvement
Focal areas of necrosis
Cardiomyopathy from 8 weeks, ECG
abnormalities
Increased probability of spontaneous death
at 6 months
Sgcd
-/-
(129SvJ/
129SvEms-
+
Ter/J
background)
Transgenic (vector-mediated replacement of
exon 2; homozygotes generated from
heterozygote matings) [56], resultant δ-SG
mRNA lacking 201-bp region.
Loss of all SGs (including ε-SG) in
muscle microsomes on
immunoblot despite normal levels
of transcription
Premature death: only 50% survival at 28
weeks
Elevated CK
Regional degeneration/regeneration,
calcification, inflammatory infiltration,
perivascular fibrosis and increased EBD
uptake on muscle histology
Cardiac histological changes at 12 weeks
Reduced force generation in response to
eccentric contractions
Drosophila
Line 840 Engineered (large deletion by P element
excision) [65]
Loss of whole δ-SG protein
Effect on other DGC components
uncharacterized
Shortened lifespan
Progressive impairment in locomotive ability
Reduced heart tube function
Abnormal flight muscles
No regeneration
Line 28 Engineered (small deletion by P element
excision) [65]
Loss of cytoplasmic region of
δ-SG only
Effect on other DGC components
uncharacterized
Mild
Near-normal lifespan
Normal cardiac function
Normal locomotive function
Caenorhabditis
elegans
F07H5.2 RNA interference (animals fed or injected with
dsRNA corresponding to 500- to 700-bp exon-
rich region) [64]
Uncharacterized? Phenotype similar to dystrophin KO (dys-1)
(bending of head with forward movement,
hyperactivity, hypercontraction)
Zebrafish
N/A Morpholino knockdown of δ-SG [67] Downregulation of δ-, b- and
g-SGs
Disorganized muscle development
Reduced movement 5 dpf
N/A Morpholino knockdown of δ-SG [66] Uncharacterized? Severe abnormality of skeletal and cardiac
muscle
Delayed cardiac development and abnormal
cardiac differentiation
Dead by 5 dpf
aCM, cardiomyopathy; dpf, days postfertilization; KO, knockout; SG, sarcoglycan; EBD, Evans blue dye; LV, left ventricular; CK, creatine kinase; DGC, dystrophin-
glycoprotein complex; ECG, electrocardiogram; Sgcd
-/-, δ-sarcoglycan-deficient; dsRNA, double-stranded RNA.
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trophic TO-2 hamsters, which is not present in the BIO
14.6 strain, has been identified [51]. Other mapping
approaches have also led to the identification of genetic
modifiers of fibrosis, membrane leak and muscle-specific
modifying loci in another mouse model of sarcoglycano-
pathy [52,53]. Genetic modifiers may therefore partly
account for heterogeneity in both clinical presentation
and muscle involvement in patients with LGMD2F.
Another interesting difference between these two strains
of hamsters is the expression pattern of the SGs. Whilst
the cardiac muscle of BIO 14.6 stains weakly for a-a n dg-
SGs, the TO-2 strain does not stain for any of the SGC
components [54]. The TO-2 strain therefore provides a
‘cleaner’ background for the assessment of transduction
efficacy in gene transfer studies. Again, genetic modifiers
may account for this discrepancy between strains of δ-SG-
deficient hamsters and also in the rare patients who dis-
play a milder phenotype with partial retention of the SG
complex at the sarcolemma [55].
The δ-sarcoglycan-null mouse
While the hamster remains a useful, naturally occurring
model for δ-SG-deficient cardiomyopathy, δ-SG-defi-
cient (Sgcd
-/-) mice have also been generated [56,57].
From a young age, these mice develop typical histologi-
cal features of MD in most of their skeletal muscles. As
in the hamster, the diaphragm shows a particularly
severe pathology with abnormalities evident from as
early as 4 weeks of age [57].
Sgcd
-/- mice also develop cardiomyopathy from around
8 weeks of age, with focal areas of fibrosis that were
thought to be related to abnormalities in the coronary
vasculature [57]. The primacy of these vascular events
in the development of MD is contentious, however.
Functionally, 8-week-old Sgcd
-/- mouse hearts show
electrocardiographic abnormalities [57], and by
16 weeks, they develop a well-compensated cardiomyo-
pathy, with reduced contractility but preserved ejection
fraction (EF) and CO [58,59]. However, by 32 weeks of
age, there is a deterioration in pathology such that the
left (and right) EF is significantly reduced, with evidence
of right ventricular dilation, which is indicative of pul-
monary dysfunction [60]. Pulmonary dysfunction is con-
sistent with the severe pathology observed in the
diaphragms of Sgcd
-/- mice and is also a feature of
advanced stage LGMD [9,61]. The Sgcd
-/- mouse, there-
fore, like the hamster, recapitulates many of the impor-
tant features of the human disease, making it a useful
preclinical research tool.
Fly, worm and fish models of δ-SG deficiency
D e s p i t et h e i re a r l ye v o l u t i o n a r yd i v e r g e n c ef r o mm a m -
mals, δ-SG deficiency orthologues have been identified
in Drosophila, zebrafish and the nematode Caenorhabdi-
tis elegans [62-64] (Figure 1). These organisms are easy
to manipulate genetically while being cheap to breed
and maintain. They have been particularly useful in indi-
cating the protein domains that are most important to
δ-SG function [65] and for investigation of the develop-
mental expression of δ-SG in different tissues [63,66,67].
RNA interference work in C. elegans has also generated
important data suggesting the involvement of calcium
channel disruption in the pathology of MD [68].
Putative disease mechanisms
Calcium overload: a unifying mechanism?
S t u d i e si na n i m a lm o d e l so fδ-sarcoglycanopathy have
revealed a baffling array of pathological changes, which
have been targeted by various drug therapies (Figure 2).
However, many of these mechanisms can be traced to
an upstream elevation in intracellular calcium. Indeed,
c a l c i u mo v e r l o a di ss u f f i c i e n tt oe l i c i taM Dp h e n o t y p e
in mice [69]. In δ-sarcoglycanopathy, calcium overload
is thought to occur through two main mechanisms:
through membrane tears due to loss of sarcolemmal sta-
bility and through abnormalities in calcium channels of
the sarcolemmal or sarcoplasmic reticulum number or
function.
Loss of membrane integrity
The membrane instability theory of muscle pathology
predicts that the loss of components of the DGC leads
to susceptibility to contraction-induced damage,
increased influx of calcium and ultimately cell degenera-
tion. There is evidence to suggest that this is a common
primary pathomechanism in a number of MDs [70].
More specifically, membrane fragility and abnormalities
(‘Δ lesions’) have been noted in patients and in animal
models of sarcoglycanopathy [71,72]. A study using the
TO-2 hamster suggested that this sarcolemmal fragility
is due to a secondary loss of dystrophin [73]. Dystrophin
loss is not a feature of all strains of δ-SG hamster [47],
however, suggesting that loss of SGC alone is sufficient
to produce sarcolemmal instability. Sarcolemmal damage
can be easily assayed in animal models by means of
Evans blue dye (EBD), which cannot enter intact cells.
Mouse and hamster models of δ-sarcoglycanopathy both
show evidence of increased EBD uptake, in both heart
and skeletal muscles [47,57,58].
Calcium channel dysregulation
Besides the structural role of δ-SG, it has been proposed
that loss of the components of the DGC can produce a
more specific alteration in calcium influx via disruption
of calcium channels. There have been no studies con-
ducted to date suggesting a direct interaction between
the SG complex and calcium channels; however, electro-
physiological studies of myocytes isolated from dys-
trophic hamsters have shown the presence of abnormal
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levels even in the absence of mechanical stress [74].
Attempts to identify the origin of these abnormal cur-
rents in cardiomyocytes from δ-SG-deficient hamsters
have yielded contradictory evidence. While it has been
suggested that L-type calcium channels (LCCs), the pre-
dominant calcium channel in the heart, are neither
more active nor overexpressed in the hamster [75-77],
LCC antagonists (tranilast, diltiazem and FK506) have
had a protective effect on muscle [76]. Also, increased
enrichment of the pore-forming subunit of the LCC has
been found in microsomes of myopathic hearts,
although not from ventricular myocytes [78].
Other electrophysiological studies have identified
T-type calcium channels as being important in the
abnormal calcium homeostasis of δ-SG-deficient ham-
ster cardiomyocytes [79,80]. Indeed, T-type channel
blockers that have low LCC activity (efonidipine and
mibefradil) improve cardiac function in the hamster
[81,82]. However, a comparison of mibefradil and vera-
pamil efficacy in preventing the dystrophic process in
hamsters showed no benefit of mibefradil [83].
In skeletal muscle, the calcium entry required for con-
tractile activity enters via store-operated and stretch-
activated calcium channels (SOCs and SACs, respec-
tively) [84]. Elevated SAC currents have been detected
in δ-SG-deficient myotubes [85], and although transient
receptor potential canonical 1 (TRPC1) has been sug-
gested as a candidate SAC involved in the pathogenesis
of the mdx mouse model of DMD and cardiomyopathy
[86,87], there have been no studies of this channel in
δ-sarcoglycanopathy.
Some evidence points towards there being abnormal-
ities in internal calcium homeostasis across the SR
membrane in δ-SG-deficient animals [40,88]. Indeed, a
recent study of Sgcd
-/- mice suggested that two isoforms
of δ-SG (SG1 and SG3) play a role in the stabilisation of
g-SG and sarcospan expression in the T-tubule and SR
membrane [89]. The authors showed that Sgcd
-/- mice
possess a conformational change in SERCA1 Ca
2+-
ATPase (sarco(endo)plasmic reticulum ATPase 1),
which alters resting calcium homeostasis. Additionally,
it has been demonstrated that SG3 is located in close
proximity to voltage-sensing dihydropyridine receptors
that play a role in regulating calcium release via ryano-
dine receptors in the SR [40]. These findings may
explain earlier observations in the J2N-k hamster which
suggested that SR abnormalities contribute to contractile
dysfunction in these animals [90]. Therapeutic strategies
for δ-sarcoglycanopathy, then, should perhaps aim to
correct internal calcium homeostasis as well as reduce
calcium influx across the sarcolemma.
Figure 1 Alignment of δ-sarcoglycan (δ-SG) in different species illustrating conserved regions. δ-SG is a transmembrane protein (residues
are coloured according to hydrophobicity, with the most hydrophobic residues shown in red and the least hydrophobic residues shown in
blue) with several highly conserved regions. Human δ-SG is differentially spliced to produce three proteins, which differ at their C-terminus.
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Oxidative Stress and mitochondrial dysfunction
Mitochondrial swelling is commonly observed in MD,
and early electromicroscopy studies in tissues and cells
isolated from the cardiomyopathic hamster revealed sev-
eral abnormalities in the fine structure of the mitochon-
dria [91,92]. Other studies have suggested, however, that
these changes are secondary to increased intracellular
calcium and that mitochondrial swelling due to calcium
overload can lead to myocyte necrosis [93-96]. Although
latent mitochondrial dysfunction can be observed at
high heart rates in younger δ-SG-deficient hamsters, it
is ameliorated by verapamil, lending further support to
calcium involvement [97]. Increased reactive oxygen
species (ROS) production due to mitochondrial overload
is also thought to cause activation of Src kinase and
subsequent activation of TRPC1 at the sarcolemma [86].
Mitochondrial dysfunction may therefore feed back to
calcium channels on the sarcolemma to exacerbate
already elevated intracellular calcium levels. ROS sca-
vengers such as tiron, which have already been demon-
strated to have some success in mdx mice [86], may
therefore be useful in halting this vicious cycle in
δ-sarcoglycanopathy.
Figure 2 Putative pathomechanisms involved in δ-sarcoglycanopathy revealed by studies of the animal models of the disease. Disease
mechanisms suggested by animal studies, and their possible relationships to each other, are presented schematically. Pivotal events in the
development of pathology are highlighted in red, and potential therapies are shown in blue. Faded boxes represent therapies that have had
some success in animal models of other muscular dystrophies or are currently used in Duchenne muscular dystrophy and as such may be
potentially useful in the treatment of δ-sarcoglycanopathy.
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of the mitochondrial transition pore (MPTP) in δ-SG-
deficient hamster cardiomyocytes renders the mitochon-
dria of these hamsters leaky to calcium influx and
susceptible to mitochondrial swelling [93]. Mitochon-
drial swelling has been targeted directly as a strategy for
the treatment of patients with LGMD2F. Deletion of the
gene encoding cyclophilin D, a component of MPTP,
renders mice unsusceptible to mitochondrial swelling
and ameliorates pathology in Sgcd
-/- mice [98]. Indeed,
treatment with a cyclophilin D inhibitor (Debio-025) is
effective in reducing pathology in Sgcd
-/- mice and also
in the mdx mouse model of DMD [98]. This may sug-
gest that mitochondrial swelling is a common down-
stream cause of pathology in both LGMD2F and DMD.
In addition to calcium overload, defects in carnitine
transport have been implicated in mitochondrial dys-
function in δ-sarcoglycanopathy. Reduced carnitine
levels can be detected at a prepathological time point in
δ-SG-deficient hamsters [99]. L-Carnitine facilitates the
transport of fatty acids into mitochondria for energy
production via oxidation, and carnitine deficiency syn-
drome results in muscle weakness, so it can be envi-
saged that deficiency in this molecule could account for
some of the symptoms of LGMD2F. There have been a
number of studies that have suggested that supplemen-
tation with L-carnitine or propionyl-L-carnitine can
have positive effects on δ-SG mouse hearts and skeletal
muscle, in terms of both energy metabolism and pathol-
ogy [100-106]. Similarly, other dietary supplements such
as selenium, taurine and coenzyme Q10 [106,107], as
well as mild exercise regimes [108-110], have shown a
beneficial effect on mitochondrial function and hence
muscle pathology in the cardiomyopathic hamster, pro-
viding further evidence of lifestyle factors which may
influence disease progression. Therapeutically, mito-
chondrial dysfunction may therefore represent a rather
downstream but relatively easily targeted disease
mechanism.
Vascular dysfunction
Although δ-SG is expressed in vascular smooth muscle,
vascular dysfunction as a primary cause of MD pathol-
ogy is controversial. Adenoviral transfer of δ-SG into
Sgcd
-/- mice was sufficient to prevent MD, although vas-
cular smooth muscle was not transduced, suggesting
that vascular dysfunction is not a primary cause of
pathology [111-113]. Early data which showed that the
vasodilator verapamil could ameliorate ‘microinfarcts’
and focal areas of fibrosis in the Sgcd
-/- mouse and the
BIO 14.6 Syrian hamster [112-115] was originally taken
as evidence in support of the vasospasm theory. How-
ever, the interpretation of these data is muddied by the
fact that verapamil can affect LCCs in cardiomyocytes
as well as in smooth muscle and hence may normalise a
myocyte-intrinsic defect [116]. In support of this
hypothesis, a g-SG-deficient mouse with no perturbation
in vascular smooth muscle SGs develops cardiomyopa-
thy and vasospasms, presumably secondary to cardio-
myocyte degeneration [117]. Furthermore, Shimizu et al.
[118] showed that progressive myocyte loss is responsi-
ble for deterioration of cardiac function in BIO TO-2
hamsters, while impaired vascular regeneration may be
responsible for progressive remodelling. The general
view is therefore that vascular spasm is an important
mechanism that contributes to the progression of
LGMD2F, but that it should be seen as a secondary con-
sequence of myocyte injury through calcium-activated
processes such as increased proteolysis by calpains [119]
and mitochondrial dysfunction.
One of the factors that may make δ-SG-deficient ani-
mals particularly susceptible to vasospasm and focal
ischaemia is disruption of nNOS. Displacement of
nNOS from the sarcolemmal membrane has been
noted in patients with DMD and more recently in
LGMD patients with SG mutations and animal models
of sarcoglycanopathy [35,120]. nNOS is associated with
dystrophin at the sarcolemmal membrane [34] and
generates NO, a molecule with a pivotal role in modu-
lating blood flow [121], through a calcium-dependent
process. It is thought that disruption of nNOS renders
the muscle more susceptible to focal ischaemia and
damage by superoxides [121,122]. That nNOS has a
role in vascular dysfunction in δ-sarcoglycanopathy is
further evidenced by the observation that drugs which
increase myocardial NO (for example, simvastatin,
losartan) also improve cardiomyopathy in the hamster
[123-125].
Overactivation of the renin-angiotensin system may
also contribute to vasospasm in the δ-SG-deficient ham-
ster [123,126-128]. Indeed, the use of angiotensin-
converting enzyme inhibitors (ACEi) and aldosterone
antagonists has demonstrated some success in amelior-
ating cardiac and diaphragmatic pathology and function
in both hamster and mouse models of δ-SG deficiency
[129-132]. ACEi have well-established vasodilative
actions and form part of the cardiac management for
LGMD2F patients. They may have additional benefit,
however, because of their less well-characterised antifi-
brotic actions [133].
Therapeutic strategies
Current therapeutic strategies
There is currently no cure for LGMD2F and other mus-
cular dystrophies involving the DGC. Current clinical
management is similar to that described in published
care guidelines for DMD [11,134] and concentrates on
management of cardiac and respiratory symptoms. Ster-
oids are not routinely used in the treatment of
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efficacy in sarcoglycanopathies.
Replacing defective genes or proteins
Viral vector-mediated gene transfer
Intuitively, correction of the genetic defect or replace-
ment or substitution of δ-SG protein is the simplest
approach to tackling LGMD2F. Indeed, δ-SG has a
much shorter coding sequence than dystrophin and as
such may not lead to many of the difficulties that are
encountered in gene therapy for DMD. Studies in mdx
mice, however, have shown that cardiac tissue is parti-
cularly difficult to target and skeletal muscle-centric
treatment carries the danger of producing a more
aggressive cardiac phenotype [135].
Intramuscularly administered adeno-associated viral
(AAV) vectors have successfully restored cardiac and
skeletal muscle SG membrane proteins in the δ-SG-defi-
cient mouse and hamster, slowing functional deteriora-
tion [136-140]. Furthermore, it has been demonstrated
that AAV transduction can be efficient and long-lived
[141]. From a translational point of view, therapies that
can be delivered systemically are more feasible, and it
has been shown that systemically delivered AAV vectors
are also efficient in reconstituting the SGC while
reducing functional deterioration in the cardiac muscle
of δ-SG-null mice and, encouragingly, in relatively old
BIO 14.6 hamsters [142,143]. Work using virus display
peptide libraries has suggested that systemically admi-
nistered AAV vectors can also be specially selected to
‘home’ in to specific tissues, allowing greater control of
where the vector is delivered [144].
Despite these encouraging results from various animal
studies, the therapeutic approach is not easily translata-
ble to humans because of potential immunogenic and
toxic complications; however, there have already been
promising results in patients with a-SG deficiency
[145,146].
Autologous and nonautologous cell-based therapies for
δ-SG deficiency
Skeletal muscle is a source of myosphere-derived pro-
genitor cells (MDPCs), which are multipotent cells that
express a number of embryonic stem cell markers and
differentiate into vascular smooth muscle cells and
mesenchymal progeny. They have been shown to
enhance neoangiogensis and restore δ-SG expression in
the vasculature of Sgcd
-/- mice [147]. MDPCs also pro-
mote secretion of paracrine effectors such as hepatocyte
growth factor and stromal cell-derived factor 1, which
are beneficial to cardiac function. Stem cells from
patients can be pathologically impaired, however, such
that other, nonautologous cell therapy approaches may
be necessary.
Nonautologous cell therapy circumvents some pro-
blems associated with the quality and quantity of cells
isolated for an autologous cell therapy approach. How-
ever, human leukocyte antigen incompatibility of nonau-
tologous stem cells normally necessitates the use of
immunosuppressive drugs, which have unattractive side
effects. A recent study in TO-2 hamsters suggested that
mesenchymal stem cells, which express a nonimmuno-
genic phenotype, may have potential as a source for
nonautologous cell therapy that does not require immu-
nosuppression [148]. Recently, intramyocardial injection
with human umbilical cord mononuclear cells was
shown to decrease fibrosis and increase short-term car-
diac function in TO-2 hamsters [149]. Again, as with
AAV gene transfer, approaches that have had success in
animals may not be acceptable to the human immune
system.
Conclusions
It is evident that δ-SG deficiency causes a complex and
multifactorial pathology for which a combinatorial ther-
apeutic strategy may be necessary. The clinical manifes-
tation of the disease is heterogeneous, with evidence of
genetic modifiers. There are currently a number of
potential therapeutic agents which target downstream
defective pathways, but correction of the primary defect
via gene or cell therapy may prove to be the most effec-
tive treatment strategy in the future. A focus on transla-
tional research is most important to ensure that patients
benefit from our improved understanding of the patho-
physiology implicated in δ-SG deficiency.
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